| 产品名称： | 50-6 PTA-227 |
|---|---|
| 商品货号： | TS212841 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | carcinoma |
| Applications： | The antibody specifically inhibits in vivo metastasis of the human epidermoid carcinoma cell line, HEp-3. It appears to inhibit an early step in the formation of metastatic foci. The antibody may be useful for treating and diagnosing metastatic tumors. |
| Storage Conditions： | liquid nitrogen vapor phaseliquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with NS0 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against PETA-3 (CD151) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against PETA-3 (CD151) |
| Comments： | Animals were immunized with metastatic human epidermoid carcinoma (HEp-3) cells by subtractive immunization. Spleen cells were fused with NS0 myeloma cells. The antibody specifically inhibits in vivo metastasis of the human epidermoid carcinoma cell line, HEp-3. It appears to inhibit an early step in the formation of metastatic foci. The antibody may be useful for treating and diagnosing metastatic tumors. A culture of 50-6 was deposited with the ATCC as PTA-227 in June of 1999. The cell line grown at ATCC is available as CRL-2696. The original patent deposit is available as PTA-227. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phaseliquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG1 |
| Name of Depositor： | Research Fndn. SUNY |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,245,898 dated Jun 12 2001 Testa JE, et al. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 59: 3812-3820, 1999. PubMed: 10447000 Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,498,014 dated Dec 24 2002 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 50-6 PTA-227 |
|---|---|
| 商品货号： | TS212841 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | carcinoma |
| Applications： | The antibody specifically inhibits in vivo metastasis of the human epidermoid carcinoma cell line, HEp-3. It appears to inhibit an early step in the formation of metastatic foci. The antibody may be useful for treating and diagnosing metastatic tumors. |
| Storage Conditions： | liquid nitrogen vapor phaseliquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with NS0 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against PETA-3 (CD151) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against PETA-3 (CD151) |
| Comments： | Animals were immunized with metastatic human epidermoid carcinoma (HEp-3) cells by subtractive immunization. Spleen cells were fused with NS0 myeloma cells. The antibody specifically inhibits in vivo metastasis of the human epidermoid carcinoma cell line, HEp-3. It appears to inhibit an early step in the formation of metastatic foci. The antibody may be useful for treating and diagnosing metastatic tumors. A culture of 50-6 was deposited with the ATCC as PTA-227 in June of 1999. The cell line grown at ATCC is available as CRL-2696. The original patent deposit is available as PTA-227. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phaseliquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG1 |
| Name of Depositor： | Research Fndn. SUNY |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,245,898 dated Jun 12 2001 Testa JE, et al. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 59: 3812-3820, 1999. PubMed: 10447000 Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,498,014 dated Dec 24 2002 |
